Envoyer à un ami

Boehringer Ingelheim welcomes central role of LAMA/LABA therapy within 2017 GOLD Strategy for COPD

- 16 Novembre 2016 modifié le 1 Janvier 1970

• Pharmacologic treatment recommendations are tailored to patients' needs based on symptoms and exacerbation history1

• LAMA/LABA therapy now an essential cornerstone for COPD treatment across the spectrum of people with COPD in GOLD groups B-D1

• Clearer guidance for physicians on which subset of patients may benefit from the addition of ICS1

(BUSINESS WIRE)-- Boehringer Ingelheim welcomes the updated 2017 Global Initiative for Chronic Obstructive Lung Disease (GOLD) Strategy which now positions a combination of a LAMA (long-acting anticholinergic) and a LABA (long-acting beta2-agonist), as a mainstay treatment for people with Chronic Obstructive Pulmonary Disease (COPD) in GOLD groups B-D. ...

Source :